Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Importantly, expression of FGF5 and phospho-HER2 correlated with a reduced pathologic complete response rate in patients with HER2 positive breast cancer treated with neoadjuvant trastuzumab which highlights the significant role of TAFs/FGF5 in HER2 breast cancer progression and resistance. 31699826 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. 31330065 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. 31037288 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The HER2-targeted antibody-drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. 31839676 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer and is used to inform recommendations for chemotherapy. 31809240 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. 31653641 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Combined administration of anthracyclines (e.g., doxorubicin; Dox) and trastuzumab (Trz), a humanized anti-human epidermal growth factor receptor 2 (HER2; ErbB2), is an effective treatment for HER2-positive breast cancer. 31098627 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE High levels of tumor-infiltrating lymphocytes (TILs) are associated with improved prognosis and response to therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 31109192 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Treatment with dual anti-HER2 therapy for 24 weeks led to a numeric increase in pCR rate in women with HER2-positive breast cancer, without using chemotherapy. 31662331 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE In this Review, we summarize the available HER2-targeted agents and associated mechanisms of resistance, and describe the current therapeutic landscape of early stage HER2-positive breast cancer, focusing on strategies for treatment escalation or de-escalation. 31836877 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade. 31519449 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer. 31806448 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine. 31757875 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. 31548601 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab-resistant HER2-positive BC subjects. 31566722 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE There was a tendency for higher size underestimation in breast cancer tumors with high-histological grade (p=0.03), human epidermal growth factor receptor type 2 (HER2)-overexpressing breast cancer tumors (p=0.02) and hormone receptor (HR)-/HER2+ breast cancer tumors (p=0.008). 31063517 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells. 31213813 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Here, we analyse the cytotoxicity of QD-encoded microcapsules, validate an approach to the activation of the microcapsule's surface for further functionalization with monoclonal antibody Trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and already in clinical use for the treatment of HER2 positive breast cancer. 30761294 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were present or if tumor expressed PD-L1. 31475002 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. 30781624 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 31637013 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Trastuzumab is a monoclonal antibody against the human epidermal growth factor-2 (HER2) receptor and dual-labeled trastuzumab with both a fluorophore (IRDye800CW) and a radioactive label (<sup>111</sup>In) can be used for multimodal imaging of HER2-positive breast cancer. 31754913 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prognostic marker for trastuzumab resistance in HER2-positive (HER2+) breast cancer. 30265336 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Trastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is essential for the treatment of HER2-positive breast cancer. 31387614 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Together, these findings define HER2-CB<sub>2</sub>R heteromers as new potential targets for antitumor therapies and biomarkers with prognostic value in HER2-positive breast cancer. 30733293 2019